BB
VYGR icon

BB Biotech’s Voyager Therapeutics VYGR Stock Holding History

BB Biotech’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$54.9M Hold
2,865,841
– – 1.38% 24
2018
Q4 		$26.9M Buy
2,865,841
+43,200
+2% +$554K 0.86% 26
2018
Q3 		$53.4M Buy
2,822,641
+290,000
+11% +$5.56M 1.41% 22
2018
Q2 		$49.5M Buy
2,532,641
+540,000
+27% +$10.7M 1.43% 19
2018
Q1 		$37.4M Buy
1,992,641
+453,121
+29% +$9.79M 1.03% 21
2017
Q4 		$25.6M Buy
+1,539,520
New +$26.4M 0.72% 24

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BB Biotech's VYGR Position: Q1 2019 in Review

BB Biotech held its Voyager Therapeutics (VYGR) position steady in Q1 2019 at 2,865,841 shares worth $54.9M. The position accounts for 1.38% of the portfolio, ranked #24.

BB Biotech first reported a position in VYGR in Q4 2017 and has held it in 6 quarters since. 111 funds tracked by Wall St. Rank hold VYGR as of Q1 2019.

  • BB Biotech held 2,865,841 shares of Voyager Therapeutics worth $54.9M as of Q1 2019.
  • BB Biotech left its Voyager Therapeutics share count unchanged in Q1 2019.
  • Voyager Therapeutics made up 1.38% of BB Biotech's portfolio in Q1 2019, its #24 holding.
  • BB Biotech first reported a position in Voyager Therapeutics in Q4 2017 and has held it in 6 quarters since.
  • 111 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2019.

Based on BB Biotech's 13F filing for Q1 2019, filed 13 May 2019.